Abstract
As heart failure with preserved ejection fraction (HFpEF) rises to epidemic proportions, major steps in patient management and therapeutic development are badly needed. With the current position paper we seek to update our view on HFpEF as a highly complex systemic syndrome, from risk factors and mechanisms to long-term clinical manifestations. We will revise recent advances in animal model development, experimental set-ups and basic and translational science approaches to HFpEF research, highlighting their drawbacks and advantages. Directions are provided for proper model selection as well as for integrative functional evaluation from the in vivo setting to in vitro cell function testing. Additionally, we address new research challenges that require integration of higher-order inter-organ and inter-cell communication to achieve a full systems biology perspective of HFpEF.
| Original language | English |
|---|---|
| Pages (from-to) | 216-227 |
| Number of pages | 12 |
| Journal | European Journal of Heart Failure |
| Volume | 20 |
| Issue number | 2 |
| Early online date | 16 Nov 2017 |
| DOIs | |
| Publication status | Published - 28 Feb 2018 |
Fingerprint
Keywords
- Animal models
- Experimental evaluation
- Heart failure with preserved ejection fraction
- Molecular biology
- Myocardial function
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
An integrative translational approach to study heart failure with preserved ejection fraction : a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. / Lourenço, Andre P.; Leite-Moreira, Adelino F.; Balligand, Jean Luc; Bauersachs, Johann; Dawson, Dana; de Boer, Rudolf A.; de Windt, Leon J.; Falcão-Pires, Inês; Fontes-Carvalho, Ricardo; Franz, Stefan; Giacca, Mauro; Hilfiker-Kleiner, Denise; Hirsch, Emilio; Maack, Christoph; Mayr, Manuel; Pieske, Burkert; Thum, Thomas; Tocchetti, Carlo G.; Brutsaert, Dirk L.; Heymans, Stephane.
In: European Journal of Heart Failure, Vol. 20, No. 2, 28.02.2018, p. 216-227.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - An integrative translational approach to study heart failure with preserved ejection fraction
T2 - a position paper from the Working Group on Myocardial Function of the European Society of Cardiology
AU - Lourenço, Andre P.
AU - Leite-Moreira, Adelino F.
AU - Balligand, Jean Luc
AU - Bauersachs, Johann
AU - Dawson, Dana
AU - de Boer, Rudolf A.
AU - de Windt, Leon J.
AU - Falcão-Pires, Inês
AU - Fontes-Carvalho, Ricardo
AU - Franz, Stefan
AU - Giacca, Mauro
AU - Hilfiker-Kleiner, Denise
AU - Hirsch, Emilio
AU - Maack, Christoph
AU - Mayr, Manuel
AU - Pieske, Burkert
AU - Thum, Thomas
AU - Tocchetti, Carlo G.
AU - Brutsaert, Dirk L.
AU - Heymans, Stephane
N1 - We acknowledge the support from the Netherlands Cardiovascular Research Initiative: ‘An initiative with support of the Dutch Heart Foundation’, CVON-ARENA. APL, ALM, IFP and RFC, grants from Fundação para a Ciência e Tecnologia (PTDC/DTP-PIC/4104/2014 and EXCL/BIM --MEC/0055/2012, financiados por fundos nacionais através da FCT - Fundação para a Ciência e Tecnologia, I.P. e cofinanciados pelo FEDER - Fundo Europeu de Desenvolvimento Regional, PTDC/DTP-PIC/4104/2014, através do COMPETE 2020 - Programa Operacional Fatores de Competitividade), FP7-Health-2010, MEDIA-261409, MINOTAUR, ERA-NET-CVD 2017, ‘Diabetes obesity at the crossroads between Oncological and Cardiovascular diseases - a system analysis NET towards precision medicine (DOCnet)’ (NORTE-01 -0145-FEDER-000003) and ‘NEw Targets in DIAstolic heart failure: from co-MOrbidities to persoNalizeD medicine (NETDIAMOND)’ (SAICT-PAC/0047/2015; 01/12/2016 to 30/11/2019), grants from EU through the European Regional Development Fund (ERDF), European Structural and Investment Funds (ESIF), under Lisbon Portugal Regional Operational Programme and National Funds through FCT.
PY - 2018/2/28
Y1 - 2018/2/28
N2 - As heart failure with preserved ejection fraction (HFpEF) rises to epidemic proportions, major steps in patient management and therapeutic development are badly needed. With the current position paper we seek to update our view on HFpEF as a highly complex systemic syndrome, from risk factors and mechanisms to long-term clinical manifestations. We will revise recent advances in animal model development, experimental set-ups and basic and translational science approaches to HFpEF research, highlighting their drawbacks and advantages. Directions are provided for proper model selection as well as for integrative functional evaluation from the in vivo setting to in vitro cell function testing. Additionally, we address new research challenges that require integration of higher-order inter-organ and inter-cell communication to achieve a full systems biology perspective of HFpEF.
AB - As heart failure with preserved ejection fraction (HFpEF) rises to epidemic proportions, major steps in patient management and therapeutic development are badly needed. With the current position paper we seek to update our view on HFpEF as a highly complex systemic syndrome, from risk factors and mechanisms to long-term clinical manifestations. We will revise recent advances in animal model development, experimental set-ups and basic and translational science approaches to HFpEF research, highlighting their drawbacks and advantages. Directions are provided for proper model selection as well as for integrative functional evaluation from the in vivo setting to in vitro cell function testing. Additionally, we address new research challenges that require integration of higher-order inter-organ and inter-cell communication to achieve a full systems biology perspective of HFpEF.
KW - Animal models
KW - Experimental evaluation
KW - Heart failure with preserved ejection fraction
KW - Molecular biology
KW - Myocardial function
UR - http://www.scopus.com/inward/record.url?scp=85034266241&partnerID=8YFLogxK
U2 - 10.1002/ejhf.1059
DO - 10.1002/ejhf.1059
M3 - Article
AN - SCOPUS:85034266241
VL - 20
SP - 216
EP - 227
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1388-9842
IS - 2
ER -